2 results
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMOCompleted
The primary objective is to determine the limited-efficacy of both the experimental systems in comparison to our previous cohort that was treated with the more traditional MCGR. Limited-efficacy will be determined in terms of maintenance of theā¦